On December 4, 2023, Nanobiotix S.A. closed the transaction. The company issued 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares at a price $5.36 for a gross proceeds $4,830,732.16 in its second and final tranche, the company has issued total 4,664,179 shares for total gross proceeds of $24,999,999.44 in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.21 EUR | +0.49% | +14.05% | -6.48% |
04-25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 | |
04-24 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.48% | 313M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.